Xvivo Perfusion AB Total Assets
Xvivo Perfusion AB total assets. Based on the latest financial reports, Xvivo Perfusion AB (XVIVO) holds total assets worth Skr2.53 Billion SEK (≈ $271.93 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Xvivo Perfusion AB for the company's overall valuation and market capitalisation.
Total Assets of Xvivo Perfusion AB (2011–2025)
Total assets of Xvivo Perfusion AB from 2011 to 2025. This chart illustrates how Xvivo Perfusion AB's total assets have evolved over time, based on quarterly financial data. See current stock price of Xvivo Perfusion AB for real-time trading data and today's change.
Xvivo Perfusion AB - Asset Composition Analysis
Xvivo Perfusion AB Total Assets Breakdown (December 2025)
Xvivo Perfusion AB total assets breakdown as of December 2025. Xvivo Perfusion AB's total assets of Skr2.53 Billion consist of 29.0% current assets and 71.0% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr292.09 Million | 12.3% |
| Accounts Receivable | Skr147.66 Million | 6.2% |
| Inventory | Skr248.46 Million | 10.5% |
| Property, Plant & Equipment | Skr213.88 Million | 9.0% |
| Intangible Assets | Skr840.29 Million | 35.4% |
| Goodwill | Skr610.06 Million | 25.7% |
Asset Composition Trend (2011–2025)
This chart illustrates how Xvivo Perfusion AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore XVIVO net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xvivo Perfusion AB's current assets represent 29.0% of total assets in 2025, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 12.3% of total assets in 2025, up from 1.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 60.0% of total assets, an increase from 1.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 35.4% of total assets.
Xvivo Perfusion AB Competitors by Total Assets
Key competitors of Xvivo Perfusion AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
GN Store Nord
CO:GN
|
Denmark | Dkr29.23 Billion |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212
|
China | CN¥1.86 Billion |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €13.91 Million |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
Xvivo Perfusion AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.86 | 4.81 | 6.59 |
| Quick Ratio | 2.65 | 3.13 | 5.33 |
| Cash Ratio | 0.00 | 2.01 | 4.54 |
| Working Capital | Skr540.02 Million | Skr612.49 Million | Skr350.28 Million |
Xvivo Perfusion AB - Advanced Valuation Insights
This section examines the relationship between Xvivo Perfusion AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.02 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | -1.2% |
| Total Assets | Skr2.37 Billion |
| Market Capitalization | $694.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values Xvivo Perfusion AB's assets below their book value (0.29x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Xvivo Perfusion AB's assets decreased by 1.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Xvivo Perfusion AB (2011–2025)
The table below shows the annual total assets of Xvivo Perfusion AB from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr2.37 Billion ≈ $255.49 Million |
-1.19% |
| 2024-12-31 | Skr2.40 Billion ≈ $258.57 Million |
+9.43% |
| 2023-12-31 | Skr2.20 Billion ≈ $236.28 Million |
+26.69% |
| 2022-12-31 | Skr1.73 Billion ≈ $186.51 Million |
+12.35% |
| 2021-12-31 | Skr1.54 Billion ≈ $166.01 Million |
+34.10% |
| 2020-12-31 | Skr1.15 Billion ≈ $123.79 Million |
+81.30% |
| 2019-12-31 | Skr634.49 Million ≈ $68.28 Million |
+8.16% |
| 2018-12-31 | Skr586.61 Million ≈ $63.13 Million |
+8.93% |
| 2017-12-31 | Skr538.54 Million ≈ $57.96 Million |
+54.18% |
| 2016-12-31 | Skr349.30 Million ≈ $37.59 Million |
+71.07% |
| 2015-12-31 | Skr204.18 Million ≈ $21.97 Million |
+1.23% |
| 2014-12-31 | Skr201.70 Million ≈ $21.71 Million |
+58.12% |
| 2013-12-31 | Skr127.56 Million ≈ $13.73 Million |
+11.39% |
| 2012-12-31 | Skr114.52 Million ≈ $12.32 Million |
-18.71% |
| 2011-12-31 | Skr140.88 Million ≈ $15.16 Million |
-- |
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidn… Read more